Chlorphenamine/codeine controlled release - Spriaso

Drug Profile

Chlorphenamine/codeine controlled release - Spriaso

Alternative Names: Chlorphenamine maleate/codeine phosphate extended release - Spriaso; Chlorpheniramine/codeine; Codeine/chlorpheniramine; LPCN 1084; Rinotuss12; Tuxarin ER

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lipocine
  • Developer Spriaso
  • Class Antitussives; Morphinans; Opioid analgesics; Sedating antihistamines
  • Mechanism of Action Histamine H1 receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Common cold; Cough

Most Recent Events

  • 08 Dec 2017 Chemical structure information added
  • 22 Jun 2015 Registered for Common cold in USA (PO)
  • 22 Jun 2015 Registered for Cough in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top